改革开放以来,国内新药开发事业欣欣向荣,为临床提供了不少安全、有效的药品。然而,有的药物研制单位未作详尽的调查,单凭文献报道或主观臆想确定开发的品种,结果花费了大量的人力与财力,而新品种并不能被临床广泛应用。类似的教训必须记取。 如何确定适应临床需要、有开发价值的新品种呢?结合抗生素的实际,提出以下观点。 1 临床迫切需要而又缺项的品种开发价值大 从国内临床分离菌的种类与耐药状况分析来看,70年 Since the reform and opening up, the cause of new drug development in our country has thrived, providing a lot of safe and effective medicines for clinical use. However, some drug research institutes did not make detailed investigations. Specially determined cultivars based on literature reports or subjective assumptions have resulted in a large amount of manpower and financial resources being spent, and new varieties can not be widely used clinically. A similar lesson must be taken. How to determine adapt to the clinical needs of the development of new varieties of value it? Combined with the actual antibiotics, put forward the following points. An urgent need for clinical and lack of variety development value from the clinical isolates of domestic species and resistant status analysis, 70 years